Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 + Chemo + Bevacizumab in Platinum-Resistant Ovarian Cancer
NCT06509971Phase 2Not yet recruiting
- Sponsor
- West China Second University Hospital
- Start
- Jul 2024
- Primary completion
- Feb 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
01
Overview
A Phase 2 trial of QL1706 in ovarian cancer, sponsored by West China Second University Hospital. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT06509971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06509971.